Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Eli Lilly (NY:LLY)

805.23 -20.68 (-2.50%)
Official Closing Price Updated: 7:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Hims & Hers Adds Eli Lilly's Zepbound To Weight-Loss Offerings: Retail Excited Despite BofA Seeing 'Immaterial' Sales Impact
According to Bloomberg, a monthly prescription of Zepbound via Hims' platform would cost $1,899 — $800 more than Lilly's list price for the drug. 
Via Stocktwits
Why Major Pharmaceutical Stocks Tumbled on Tuesday
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
Why Hims & Hers Health Stock Soared Tuesday
Via The Motley Fool
Topics Stocks
Exposures US Equities
Hims & Hers Health Stock Jumped Tuesday Afternoon: What Happened?
Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co's (NYSE:LLY) Zepbound through its Telehealth platform. 
Via Benzinga
Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.5% in the afternoon session after the company revealed it will offer Eli Lilly's weight-loss medications (Zepbound) on its... 
Via StockStory
Topics Artificial Intelligence Supply Chain
Exposures Artificial Intelligence Product Safety Supply Chain
Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound
The deal allows Hims & Hers to sell Eli Lilly's Zepbound on its telehealth platform. 
Via Investor's Business Daily
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Check Out What Whales Are Doing With LLY
Via Benzinga
Biotech Stocks Take Another Beating As 'Chaos' Reigns At FDA With Reports Of Mass Firings
Reports of mass firings include another high-profile official as Robert F. Kennedy Jr. and Marty Makary take up their new roles. 
Via Investor's Business Daily
Topics Workforce
Exposures COVID-19 Layoff Product Safety
If Nearly Half of S&P 500 Stocks Are Up in 2025, Then Why Is the Index Down 5%?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Where Will Eli Lilly Be in 1 Year?
The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns. 
Via The Motley Fool
Exposures Product Safety
The Vanguard S&P 500 ETF Is Sinking, but This Wall Street Analyst Predicts It Will Soar 168% by 2030
Via The Motley Fool
Topics ETFs Economy Stocks
Exposures Economy US Equities
Who Is Peter Thiel's Protégé, Michael Kratsios, Now Leading Trump's AI Strategy Amid Rising Tech Tensions With China
Michael Kratsios, former deputy to Peter Thiel, has been appointed to lead the U.S. government's AI strategy amid escalating competition with China, as tensions rise over China's DeepSeek AI model and... 
Via Benzinga
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Eli Lilly's Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%
Eli Lilly's lepodisiran met Phase 2 trial goals, significantly lowering Lp(a) levels. A Phase 3 study is enrolling to assess its impact on cardiovascular events. 
Via Benzinga
Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight
Palatin's study shows co-administering bremelanotide with tirzepatide led to greater weight loss than tirzepatide alone, with further analysis ongoing. 
Via Benzinga
Which Healthcare Stock Is the Best Buy Right Now?
Healthcare stocks provide a combination of upstarts with a high risk, high reward proposition to established firms that can be a defensive maneuver. 
Via MarketBeat
1 Growth Stock With Major Catalysts on the Way to Buy and Hold
Via The Motley Fool
Is Hims & Hers Stock Too Cheap to Pass Up?
This high-growth stock may be cheaper than you think. 
Via The Motley Fool
Benzinga Bulls And Bears: Chevron, Microsoft, Nike — And Tariffs Have Automotive Sector Reeling
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Microsoft Co-Founder Bill Gates Praises China As A Pioneer In Solar, Batteries, And AI: Warns Tensions Are Stifling Global Innovation
Bill Gates criticized escalating U.S.-China tensions for hindering global access to critical green technologies, praising China as a global leader in solar, batteries, and AI while warning that... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Eli Lilly Stock Up 1% After Key Signal, Despite S&P 500's ~2% Drop
Eli Lilly shares demonstrated a power inflow at $821.70, after which LLY rose up to 1%, while S&P 500 dropped nearly 2% today. 
Via Benzinga
Topics Stocks
Exposures US Equities
European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen
Eli Lilly's donanemab faces a setback as EMA's CHMP issues a negative opinion. Analysts expect Lilly to appeal, citing past reversals in similar cases. 
Via Benzinga
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1
The company is looking for drugs it can add to Wegovy to improve the amount of weight lost. 
Via Investor's Business Daily
Investors Are Flocking to These 3 Vanguard Sector ETFs. Should You Buy Them Too?
Via The Motley Fool
Topics ETFs Economy Government
Exposures Economy Political Tariff
Billionaires Stanley Druckenmiller, Chase Coleman, and Stephen Mandel Jr. Are Piling Into This Growth Stock That's Beating the S&P 500
Via The Motley Fool
Topics Stocks
Exposures US Equities
Here's How Much $1000 Invested In Eli Lilly 20 Years Ago Would Be Worth Today
Via Benzinga
Why Novo Nordisk Stock Dipped on Thursday
Via The Motley Fool
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Uncertainty has cast a pall over medical stocks, which are taking a "wait-and-see" approach to Trump's tariffs. 
Via Investor's Business Daily
Topics Government
Exposures Political
1 Growth Stock Down 40% to Buy and Hold Forever
Via The Motley Fool
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to the company. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.